{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:45:27Z","timestamp":1765827927674,"version":"3.32.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ijantimicag.2020.106027","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T01:45:59Z","timestamp":1590198359000},"page":"106027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-1114","authenticated-orcid":false,"given":"Maria M.","family":"Santoro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Fornabaio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Malena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Poli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Menozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten L.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106027_bib0001","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/phar.2246","article-title":"Integrase inhibitors: after 10 years of experience, is the best yet to come?","volume":"39","author":"Brooks","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","article-title":"Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir","volume":"15","author":"Oliveira","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0003","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0004","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0005","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0006","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0007","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAI.0000000000002137","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial","volume":"82","author":"Kityo","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0008","first-page":"21","article-title":"Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F\/TAF or F\/TDF)","author":"Sax","year":"2019","journal-title":"Tenth IAS Conference on HIV Science"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0009","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0010","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0011","series-title":"Abstract eBook of the 2017 Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Bictegravir dissociation half-life from HIV-1 G140S+Q148H integrase\/DNA complexes","author":"White","year":"2017"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0012","first-page":"63","article-title":"Resistance analysis of bictegravir-emtricitabine-tenofovir alafenamide in HIV-1 treatment-naive patients through 48 weeks","author":"Acosta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0013","article-title":"Keeping the pressure on archived NRTI resistance: switching to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) triple therapy in study 4030","author":"Acosta","year":"2019","journal-title":"Tenth IAS Conference on HIV Science"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0014","first-page":"111","article-title":"Update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing","year":"2019","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0015","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/jmv.25564","article-title":"Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-na\u00efve individuals","volume":"91","author":"Margot","year":"2019","journal-title":"J Med Virol"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0016","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0017","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/QAI.0b013e31826bfd02","article-title":"The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults","volume":"61","author":"Underwood","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0018","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/AAC.02568-12","article-title":"Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness","volume":"57","author":"Abram","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0019","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12977-018-0420-7","article-title":"Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants","volume":"15","author":"Smith","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0020","series-title":"2018 Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Integrase inhibitor resistance selections initiated with drug resistant HIV-1","author":"Andreatta","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0021","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/infdis\/jiy428","article-title":"Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors","volume":"218","author":"Zhang","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106027_bib0022","doi-asserted-by":"crossref","first-page":"e01717","DOI":"10.1128\/AAC.01717-19","article-title":"Comparable in vitro activities of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations","volume":"64","author":"Saladini","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ijantimicag.2020.106027_bib0023","doi-asserted-by":"crossref","first-page":"e01695","DOI":"10.1128\/AAC.01695-17","article-title":"Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1","volume":"61","author":"Hassounah","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T19:32:49Z","timestamp":1735673569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920301904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0924857920301904"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106027","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106027"}}